Decreased levels of serum oxytocin in pediatric patients with Attention Deficit/Hyperactivity Disorder

Psychiatry Research

Volumn 228, Issue 3, 2015, Pages 746-751

  Sasaki, Tsuyoshi ^a,b   Hashimoto, Kenji ^c   Oda, Yasunori ^b   Ishima, Tamaki ^c   Kurata, Tsutomu ^a   Takahashi, Junpei ^a   Kamata, Yu ^b   Kimura, Hiroshi ^b   Niitsu, Tomihisa ^b   Komatsu, Hideki ^b   Ishikawa, Masatomo ^b   Hasegawa, Tadashi ^b   Shiina, Akihiro ^a   Hashimoto, Tasuku ^b   Kanahara, Nobuhisa ^c   Shiraishi, Tetsuya ^b   Iyo, Masaomi ^a,b,c  

^a CHIBA UNIVERSITY HOSPITAL   (Japan)

^b CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c CHIBA UNIVERSITY   (Japan)

Author keywords

Amygdala; Attention Deficit Hyperactivity Disorder; Biological markers; Oxytocin; Serum

Indexed keywords

ARIPIPRAZOLE; ATOMOXETINE; METHYLPHENIDATE; OXYTOCIN; BIOLOGICAL MARKER;

ADOLESCENT; ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HORMONE DETERMINATION; HUMAN; MALE; OXYTOCIN BLOOD LEVEL; PRIORITY JOURNAL; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; AUTISM SPECTRUM DISORDER; BLOOD; COMORBIDITY; EXECUTIVE FUNCTION; PHYSIOLOGY;

ADOLESCENT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; AUTISM SPECTRUM DISORDER; BIOMARKERS; CHILD; COMORBIDITY; EXECUTIVE FUNCTION; FEMALE; HUMANS; MALE; OXYTOCIN;

EID: 84938748664     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2015.05.029     Document Type: Article

References (44)

1. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 1994, American Psychiatric Press, Washington, DC. 4th ed.
2. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 2013, American Psychiatric Publishing, Washington, DC. 5th ed.
3. Andari E., Duhamel J.R., Zalla T., Herbrecht E., Leboyer M., Sirigu A. Promoting social behavior with oxytocin in high-functioning autism spectrum disorders. Proc. Natl. Acad. Sci. 2010, 107(9):4389-4394.
4. Bale T.L., Davis A.M., Auger A.P., Dorsa D.M., McCarthy M.M. CNS region-specific oxytocin receptor expression: importance in regulation of anxiety and sex behavior. J. Neurosci. 2001, 21:2546-2552.
5. Bartz J.A., Zaki J., Bolger N., Ochsner K.N. Social effects of oxytocin in humans: context and person matter. Trends Cognit. Sci. 2011, 15:301-309.
6. Biederman J., Mick E., Surman C., Doyle R., Hammerness P., Harpold T., Dunkel S., Dougherty M., Aleardi M., Spencer T. A randomized, placebo- controlled trial of OROS methylphenidate in adults with attention- deficit/hyperactivity disorder. Biol. Psychiatry 2006, 59:829-835.
7. Corbett B.A., Constantine L.J., Hendren R., Rocke D., Ozonoff S. Examining executive functioning in children with autism spectrum disorder, attention deficit hyperactivity disorder and typical development. Psychiatry Res. 2009, 166:210-222.
8. David Wechsler., 1998. Wechsler Intelligence Scale for Children, third ed. (H.Azuma, K.Ueno, K.Fujita, H.Maekawa, T.Ishikuma, H.Sano, Trans.). The Psychological Corporation, USA: (Original work published 1991) (in Japanese).
9. David Wechsler., 2010. Wechsler Intelligence Scale for Children, forth ed. (K.Ueno, K.Fujita, H.Maekawa, T.Ishikuma, H.Dairoku, O.Matsuda, Trans.). The Psychological Corporation, USA. (Original work published 1998) (in Japanese).
10. Domes G., Heinrichs M., Gläscher J., Büchel C., Braus D.F., Herpertz S.C. Oxytocin attenuates amygdala responses to emotional faces regardless of valence. Biol. Psychiatry 2007, 62(10):1187-1190.
11. DuPaul, G.J., Power, T.J., Anastopoulos, A.D., & Reid, R., 2008. ADHD Rating Scale-IV: Checklists, norms, and clinical interpretation (H. Ichikawa & Y. Tanaka, Trans.). Akashi-shoten, Tokyo, Japan. (Original work published 1998) (in Japanese).
12. Ferguson J.N., Young L.J., Hearn E.F., Matzuk M.M., Insel T.R., Winslow J.T. Social amnesia in mice lacking the oxytocin gene. Nat. Genet. 2000, 25:284-288.
13. Ferguson J.N., Aldag J.M., Insel T.R., Young L.J. Oxytocin in the medial amygdala is essential for social recognition in the mouse. J. Neurosci. 2001, 21:8278-8285.
14. Ferguson J.N., Young L.J., Insel T.R. The neuroendocrine basis of social recognition. Front. Neuroendocrinol. 2002, 23:200-224.
15. Frodl T., Skokauskas N. Meta-analysis of structural MRI studies in children and adults with attention deficit hyperactivity disorder indicates treatment effects. Acta Psychiatr. Scand. 2012, 125(2):114-126.
16. Green L., Fein D., Modahl C., Feinstein C., Waterhouse L., Morris M. Oxytocin and autistic disorder: alterations in peptide forms. Biol. Psychiatry 2001, 50(8):609-613.
17. Guastella A.J., Einfeld S.L., Gray K.M., Rinehart N.J., Tonge B.J., Lambert T.J., Hickie I.B. Intranasal oxytocin improves emotion recognition for youth with autism spectrum disorders. Biol. Psychiatry 2009, 67(7):692-694.
18. Hill EL. Executive dysfunction in autism. Trends Cognit. Sci. 2004, 8:26-32.
19. Hollander E., Novotny S., Hanratty M., Yaffe R., DeCaria C.M., Aronowitz B.R., Mosovich S. Oxytocin infusion reduces repetitive behaviors in adults with autistic and Asperger[U+05F3]s disorders. Neuropsychopharmacology 2003, 28(1):193-198.
20. Hollander E., Bartz J., Chaplin W., Phillips A., Sumner J., Soorya L., Anagnostou E., Wasserman S. Oxytocin increases retention of social cognition in autism. Biol. Psychiatry 2007, 61(4):498-503.
21. Huber D., Veinante P., Stoop R. Vasopressin and oxytocin excite distinct neuronal populations in the central amygdala. Science 2005, 308:245-248.
22. Insel T.R., O'Brien D.J., Leckman J.F. Oxytocin, vasopressin, and autism: is there a connection. Biol. Psychiatry 1999, 45:145-157.
23. Kosaka H., Munesue T., Ishitobi M., Asano M., Omori M., Sato M., Tomoda A., Wada Y. Long-term oxytocin administration improves social behaviors in a girl with autistic disorder. BMC Psychiatry 2012, 13(12):110.
24. Landgraf R., Neumann I.D. Vasopressin and oxytocin release within the brain: a dynamic concept of multiple and variable modes of neuropeptide communication. Front. Neuroendocrinol. 2004, 25:150-176.
25. Macdonald K., Feifel D. Oxytocin in schizophrenia: a review of evidence for its therapeutic effects. Acta Neuropsychiatr. 2012, 24:130-146.
26. Meyer-Lindenberg A., Domes G., Kirsch P., Heinrichs M. Oxytocin and vasopressin in the human brain: social neuropeptides for translational medicine. Nat. Rev. Neurosci. 2011, 12:524-538.
27. Modahl C., Green L., Fein D., Morris M., Waterhouse L., Feinstein C., Levin H. Plasma oxytocin levels in autistic children. Biol. Psychiatry 1998, 43(4):270-277.
28. Molina B.S., Hinshaw S.P., Swanson J.M., Arnold L.E., Vitiello B., Jensen P.S., Epstein J.N., Hoza B., Hechtman L., Abikoff H.B., Elliott G.R., Greenhill L.L., Newcorn J.H., Wells K.C., Wigal T., Gibbons R.D., Hur K., Houck P.R. The MTA at 8 years: prospective follow-up of children treated for combined-type ADHD in a multisite study. J. Am. Acad. Child Adolesc. Psychiatry 2009, 48:484-500. MTA Cooperative Group.
29. Musser E.D., Hawkey E., Kachan-Liu S.S., Lees P., Roullet J.B., Goddard K., Steiner R.D., Nigg J.T. Shared familial transmission of autism spectrum and attention-deficit/hyperactivity disorders. J. Child Psychol. Psychiatry 2014, 55(7):819-827.
30. Park J., Willmott M., Vetuz G., Toye C., Kirley A., Hawi Z., Brookes K.J., Gill M., Kent L. Evidence that genetic variation in the oxytocin receptor (OXTR) gene influences social cognition in ADHD. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2010, 34(4):697-702.
31. Polanczyk G., de Lima M.S., Horta B.L., Biederman J., Rohde L.A. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am. J. Psychiatry 2007, 164:942-948.
32. Rommelse N.N., Geurts H.M., Franke B., Buitelaar J.K., Hartman C.A. A review on cognitive and brain endophenotypes that may be common in autism spectrum disorder and attention-deficit/hyperactivity disorder and facilitate the search for pleiotropic genes. Neurosci. Biobehav. Rev. 2011, 35:1363-1396.
33. Sanders J., Johnson K.A., Garavan H., Gilla M., Gallaghera L. A review of neuropsychological and neuroimaging research in autistic spectrum disorders: attention, inhibition and cognitive flexibility. Res. Autism Spectr. Disord. 2008, 2:1-16.
34. Scassellati C., Bonvicini C., Faraone S.V., Gennarelli M. Biomarkers and attention-deficit/hyperactivity disorder: a systematic review and meta-analyses. J. Am. Acad. Child Adolesc. Psychiatry 2012, 51(10):1003-1019.
35. Shaw P., Lerch J., Greenstein D., Sharp W., Clasen L., Evans A., Giedd J., Castellanos F.X., Rapoport J. Longitudinal mapping of cortical thickness and clinical outcome in children and adolescents with attention-deficit/hyperactivity disorder. Arch. Gen. Psychiatry 2006, 63(5):540-549.
36. Sheehan D.V., Sheehan K.H., Shytle R.D., Janavs J., Bannon Y., Rogers J.E., Milo K.M., Stock S.L., Wilkinson B. Reliability and validity of the Mini International Neuropsychiatric Interview for Children and Adolescents (MINI-KID). J. Clin. Psychiatry 2010, 71(3):313-326.
37. Stavropoulos K.K., Carver L.J. Research review: social motivation and oxytocin in autism: implications for joint attention development and intervention. J. Child Psychol. Psychiatry 2013, 54(6):603-618.
38. Striepens N., Kendrick K.M., Maier W., Hurlemann R. Prosocial effects of oxytocin and clinical evidence for its therapeutic potential. Front. Neuroendocrinol. 2011, 32:426-450.
39. Tani I., Okada R., Ohnishi M., Nakajima S., Tsujii M. Japanese version of home form of the ADHD-RS: an evaluation of its reliability and validity. Res. Dev. Disabil. 2010, 31(6):1426-1433.
40. Thome J., Ehlis A.C., Fallgatter A.J., Fallgatter A.J., Krauel K., Lange K.W., Riederer P., Romanos M., Taurines R., Tucha O., Uzbekov M., Gerlach M. Biomarkers for attention-deficit/hyperactivity disorder (ADHD). A consensus report of the WFSBP task force on biological markers and the World Federation of ADHD. World J. Biol. Psychiatry 2012, 13(5):379-400.
41. Watanabe T., Abe O., Kuwabara H., Yahata N., Takano Y., Iwashiro N., Natsubori T., Aoki Y., Takao H., Kawakubo Y., Kamio Y., Kato N., Miyashita Y., Kasai K., Yamasue H. Mitigation of sociocommunicational deficits of autism through oxytocin-induced recovery of medial prefrontal activity: a randomized trial. JAMA Psychiatry 2014, 71(2):166-175.
42. Willcutt E.G., Doyle A.E., Nigg J.T., Faraone S.V., Pennington B.F. Validity of the executive function theory of attention-deficit/hyperactivity disorder: a meta-analytic review. Biol. Psychiatry 2005, 57:1336-1346.
43. Yamasue H., Yee J.R., Hurlemann R., Rilling J.K., Chen F.S., Meyer-Lindenberg A., Tost H. Integrative approaches utilizing oxytocin to enhance prosocial behavior: from animal and human social behavior to autistic social dysfunction. J. Neurosci. 2012, 32:14109-14117.
44. Yerys B.E., Wallace G.L., Harrison B., Celano M.J., Giedd J.N., Kenworthy L.E. Set-shifting in children with autism spectrum disorders: reversal shifting deficits on the intradimensional/extradimensional shift test correlate with repetitive behaviors. Autism 2009, 13:523-538.